NUCLEIC ACID APTAMER CAPABLE OF SPECIFICALLY BINDING TO TEBUCONAZOLE, MEFENACET AND INABENFIDE, AND USE THEROF
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
Sep 1, 2016
app pub date -
Oct 16, 2014
filing date -
Oct 16, 2013
priority date (Note) -
Published
status (Latency Note)
Importance
Abstract
The present invention relates to a nucleic acid aptamer capable of binding to tebuconazole, mefenacet or inabenfide, and the use thereof, and more particularly, to a nucleic acid aptamer capable of binding specifically to a very small amount of tebuconazole, mefenacet or inabenfide, and a method of detecting and separating tebuconazole, mefenacet or inabenfide using the nucleic acid aptamer. The nucleic acid aptamer of the present invention, which can bind specifically to tebuconazole, mefenacet or inabenfide, enables the detection and separation of tebuconazole, mefenacet or inabenfide present in samples such as food in very small amounts, and thus is effective for the detection and removal of tebuconazole, mefenacet or inabenfide which was difficult to detect in the prior art. In addition, because the nucleic acid aptamer of the present invention can be produced at low costs, a method and kit for detecting tebuconazole, mefenacet or inabenfide, and a kit for separating tebuconazole, mefenacet or inabenfide, which use the nucleic acid aptamer of the present invention, are cost-effective and eliminate the need to develop aptamers for various targets. Thus, the nucleic acid aptamer of the present invention is highly useful.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully